XRAY Board Decides to Retain Wellspect Healthcare; No Sale Terms Disclosed

Q: Is the press release included in the filing legally "filed" with the SEC?

The press release is furnished as Exhibit 99.1 and the filing states it is furnished, not filed, so it is not incorporated by reference into other filings absent specific reference.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. announced on September 8, 2025 that it completed its previously disclosed review of strategic alternatives for its Wellspect Healthcare business and the Board determined that Wellspect will remain within the Company’s portfolio. The Company furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing notes the exhibit is furnished (not "filed") and therefore is not incorporated by reference into other Securities Act or Exchange Act filings absent specific reference. No financial statements, transaction terms, or forward-looking guidance are included in the provided text.

Positive

Board decision reached concluding the strategic review, which removes near-term uncertainty over Wellspect’s status
Press release furnished as Exhibit 99.1, ensuring public disclosure of the Board’s determination

Negative

No financial details provided — the filing does not include valuation, transaction terms, or impact on results
Exhibit furnished, not filed which limits incorporation by reference into other filings and may reduce legal liability for the disclosed text

Insights

TL;DR: Board concluded divestiture is not pursued; decision preserves current strategic status quo.

The Board’s determination to retain Wellspect indicates management and directors concluded that continuing to own and operate the business fits the company’s strategic objectives or offers greater long-term value than a sale now. Because the filing furnishes a press release and explicitly contains no transaction terms, valuation metrics, or updated financials, the announcement primarily communicates a governance decision rather than a material change in operating results. Investors should note the company withheld further details in this Form 8-K; material financial impact is not disclosed here.

TL;DR: Outcome of strategic review: retention, not disposition; no deal terms disclosed.

The company completed a strategic-alternatives review for Wellspect and decided against a sale or carve-out based on the information provided. The filing only furnishes a press release as Exhibit 99.1 and does not present purchase offers, bidders, valuation ranges, or integration plans. From an M&A perspective, this is a close of a process rather than execution of a transaction; it removes near-term deal risk but does not provide evidence of value realization or cost/synergy outcomes.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

09/08/2025 - 08:33 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

September 8, 2025

Date of Report (Date of earliest event reported)

DENTSPLY SIRONA Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-16211

39-1434669

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

13320 Ballantyne Corporate Place,

Charlotte

North Carolina

28277-3607

(Address of principal executive offices)

(Zip Code)

(844) 848-0137

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	XRAY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure

On September 8, 2025, DENTSPLY SIRONA Inc. (the “Company”) issued a press release announcing that it has completed its previously disclosed process to evaluate strategic alternatives for its Wellspect Healthcare business (“Wellspect”) and the Company’s Board of Directors has determined that Wellspect will continue to operate within the Company’s portfolio. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:


Exhibit No.						Description

99.1						DENTSPLY SIRONA Inc. Press release issued September 8, 2025

104						Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.


By:						/s/ Richard C. Rosenzweig
						Richard C. Rosenzweig
						Executive Vice President, Corporate Development,
						General Counsel and Secretary

Date: September 8, 2025

Source: View Original Filing on SEC EDGAR

FAQ

What did DENTSPLY SIRONA (XRAY) announce about Wellspect on September 8, 2025?

The company announced its Board completed a review and determined that Wellspect will remain within the company’s portfolio.

Does the 8-K include financial terms or sale details for Wellspect?

No. The provided Form 8-K text does not include financial statements, sale terms, valuations, or transaction details.

Is the press release included in the filing legally "filed" with the SEC?

The press release is furnished as Exhibit 99.1 and the filing states it is furnished, not filed, so it is not incorporated by reference into other filings absent specific reference.

Does this 8-K indicate any change to DENTSPLY SIRONA’s financial reporting or guidance?

No. The excerpt contains no updates to financial statements, guidance, or reporting metrics.

What immediate impact does this disclosure have for investors?

The filing communicates the outcome of the strategic review (retention of Wellspect) but provides no quantitative impact or operational changes in the disclosed text.